Why is Monivent AB ?
Unrated Stock - No Analysis Available
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality key factors
Factor
Value
Sales Growth (5y)
20.68%
EBIT Growth (5y)
-32.59%
EBIT to Interest (avg)
-11.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.28
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.87
EV to EBIT
-3.14
EV to EBITDA
-3.43
EV to Capital Employed
3.13
EV to Sales
16.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-99.67%
ROE (Latest)
-140.73%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Bearish
No Trend
OBV
No Trend
No Trend
Technical Movement
0What is working for the Company
NO KEY POSITIVE TRIGGERS
-1What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 184.16% (YoY
Here's what is not working for Monivent AB
Raw Material Cost
Grown by 184.16% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales






